Skip to main content

Table 3 Numbers of patients receiving Gaucher disease specific treatments

From: The European Gaucher Alliance: a survey of member patient organisations’ activities, healthcare environments and concerns

Member association's country

Imiglucerase

Velaglucerase alfa

Eliglustat tartrate

Miglustat

Taliglucerase alfa

Other*

Total

Austria

11

5

4

1

  

21

Belgium

22

3

 

1

  

26

Bosnia & Herzegovina

3

1

0

   

4

Bulgaria

13

     

13

Canada

60

13

13

11

2

 

99

Czech Republic

21

6

 

2

  

29

Denmark

11

5

    

16

Estonia

3

     

3

Finland

6

2

 

1

  

9

Germany

230

61

9

 

1

 

301

Greece

57

6

3

6

  

72

Israel

80

160

10

 

60

5

315

Italy

113

35

 

10

  

158

Jordan

16

1

    

17

Latvia

2

     

2

Lithuania

8

     

8

Macedonia

4

     

4

Norway

5

8

    

13

Romania

55

1

2

   

58

Russia

258

6

40

   

304

Serbia

13

 

6

 

8

 

27

Slovenia

13

4

    

17

South Africa

48

  

3

5

 

56

Spain

80

50

4

30

5

 

169

Sweden

37

6

 

3

  

46

UK & RoI

112

93

2

7

5

1

220

Ukraine

36

     

36

TOTAL

1317

466

93

75

86

6

2043

% of total

64

23

5

4

4

0.3

 
  1. *Other treatments: Israel: oral enzyme replacement therapy (PRX-112) in clinical trial [Protalix, Carmiel, Israel], UK & RoI: 1 alglucerase.